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Glucuronidation is an important metabolic process for the clearance of drugs, endobiotics, and xenobiotics in all mammalian species. There are numerous instances where drugs are cleared extensively by direct glucuronidation (3Ј-azido-2Ј,3Ј-dideoxythymidine, valproic acid, propofol, and morphine; Bertz and Granneman, 1997) , although in many other cases, the involvement of glucuronidation is restricted to the conjugation of glucuronic acid to metabolites of phase I oxidative metabolism. Where drugs are significantly glucuronidated independently of phase I metabolism, the functional group to which the glucuronic acid is transferred can be a hydroxy (phenolic or aliphatic), a carboxylic acid or, in some cases, an amino group (primary, secondary, or tertiary) moiety.
The UDP-glucuronosyltransferases (UGT 1 ) family can be separated into two distinct subfamilies by sequence similarity. The UGT1 family are all derived from a single gene by alternative splicing of four constant exons (exons 2-5) to a variable exon 1. The RNA transcript leads to a transferase protein exhibiting a certain substrate specificity. The UGT2 family of isoforms are known to be encoded by individual genes (Mackenzie et al., 1997) .
Characterization of cloned and expressed human UGT has demonstrated that many UGT family 1 isoforms are capable of glucuronidating phenols to varying degrees including UGT1A1 (Senafi et al., 1994) , UGT1A3 (Green et al., 1998) , UGT1A4 (Green and Tephly, 1996) , UGT1A8, and UGT1A10 (Cheng et al., 1999) . UGT family 2 isoforms also display activity toward phenols, although substrate acceptance and rate of glucuronidation seems to be more restricted (UGT2B15, Green et al., 1994; UGT2B7, Coffman et al., 1998) . Two of the earliest UGT isoforms to be characterized were done so on the basis of their ability to glucuronidate phenols. UGT1A6 and UGT1A9 were both classified as phenol UGT isoforms due to the high turnover rates of these substrates (Ebner and Burchell, 1993) . UGT1A9 demonstrated greater proficiency in glucuronidating bulky and complex phenols than UGT1A6, which was considered to be only capable of glucuronidating simple or planer phenols (Ebner and Burchell, 1993) . The high glucuronidation activity toward simple phenolic substrates has been clearly illustrated to be present in human liver microsomes (Temellini et al., 1991) , and UGT1A6 comprises a significant proportion of liver UGT 1-naphthol glucuronidation capacity (Ouzzine et al., 1994) . Phenols have also been used as probe substrates for simple quantitative structure activity relationship modeling, although very few reports on glucuronidation quantitative structure activity relationships (QSAR) have been reported. Enzyme activity data sets for phenols and benzoic acids incubated with rabbit and rat liver microsomes, published before UGT heterogeneity were recognized (Bray et al., 1952; Mulder and Van Doorn, 1975; Illing and Benford, 1976; Mulder and Meerman, 1978) and have subsequently been used for QSAR modeling (Hansch et al., 1968; Schaefer et al., 1981; Kim, 1991) .
1 Abbreviations used are: UGT, UDP-glucuronosyltransferases; QSAR, quantitative structure activity relationship; WHIM, weighted holistic invariant molecular; MS-WHIM, molecular surface-WHIM; AT-WHIM, atomic-WHIM; UDPGA, UDP-glucuronic acid; HPLC, high-performance liquid chromatography.
These original reports and much of the data contained within has more recently been reanalyzed (Hansch and Leo, 1995) . Kinetic constants for simple phenolic substrate glucuronidation were modeled by QSAR to characterize a partially purified rat UGT (Yin et al., 1994) .
No single study to date has yet yielded enough kinetic data on an individual-expressed human UGT isoform to be able to perform any quantitative analysis. The objective of this report was to generate the kinetic parameters that describe the glucuronidation of simple 4-substituted phenols by the human UGT1A6 and UGT1A9 isoenzymes. Models were then generated for UGT1A6 and UGT1A9 from a range of molecular surface (MS-WHIM) and atomic (AT-WHIM) descriptors to determine whether the K m for phenol glucuronidation could be predicted. The models were used to look for similarities and differences in the way that these two isoforms glucuronidate phenols and were also used to determine the viability of this process for developing QSAR models for more complex and diverse substrates in the future.
Materials and Methods
Chemicals. Phenols, control substrates, UDPGA, and other reagents used in the assays were purchased from Sigma-Aldrich Ltd. (Gillingham, Dorset, UK) and British Drug Houses (Merck, Poole, Dorset, UK) and were of the highest grade available. [
14 C] UDPGA (293.6 mCi/mmol, 99.7%) was purchased from PerkinElmer Life Sciences (Stevenage, Hertfordshire, UK).
Tissue Culture. V79 and recombinant cell lines were grown using Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin (Invitrogen, Paisley, Scotland). The cloning and stable expression of the UGT isoforms has been reported elsewhere (Harding et al., 1988; Fournel-Gigleux et al., 1990; Wooster et al., 1991) . V79 cell lines heterologously expressing human UGTs were maintained under optimized constant selection concentrations of geneticin (G418; Invitrogen), V79/UGT1A6 (100 g/ml), and V79/UGT1A9 (200 g/ml). Cellular Sonication. Cells were disrupted by a standardized sonication method. Pellets containing cells harvested from two 75-cm 2 tissue culture flasks were thawed prior to assaying and resuspended in 200 l of water to lyse the cells. Each 200-l suspension of cells was sonicated for four 5 s bursts (Microson Ultrasonic Cell Disruptor; Heat Technologies, Farmingdale, New York) allowing at least 1 min on ice between bursts. Aliquots of cells prepared by this method were pooled before addition to the assays. Each set of kinetic determinations was performed using cells harvested from the same passage. Two hundred 75-cm 2 flasks of each cell line were grown expressly for this purpose.
UGT Assays. UGT assays for phenolic glucuronidation were performed as described previously (Ethell et al., 1998) . Briefly, the incubations contained 100 mM Tris/maleate buffer, pH 7.4, containing 5 mM MgCl 2 , typically 500 M substrate, 250 to 350 g of cellular sonicate, 2 mM UDPGA (0.1Ci [ 14 C] UDPGA/assay) in a total volume of 100 l. Incubations were run for 40 min and terminated by the addition of 100 l of methanol that had been prechilled at Ϫ20°C. The resulting supernatant was then transferred to an HPLC vial and 150 l of this volume directly injected onto gradient HPLC using solid scintillant radioactive detection as described previously (Ethell et al., 1998) . Product formation was linear for 1-naphthol glucuronidation, with a V max value in the same range as substrates for UGT1A6 and UGT1A9, which were most rapidly glucuronidated (Ethell et al, 1998) . Control V79 cell lines showed no detectable activity toward these substrates. It was not possible to verify that product formation was linear due to the limited availability of expressed enzyme. Every effort was made to keep protein concentration the same between batches of assays (under which conditions product formation was linear with time).
Substrate solutions were prepared and diluted on the day of assay. Typically, the range of substrate concentrations used was 10, 50, 100, 250, 500, and 1000 M. Kinetic parameters were calculated by fitting the experimental data to the Michaelis-Menten equation by a nonlinear least-squares regression method (Prism version 2; Graphpad Software, San Diego, CA).
Each kinetic determination was accompanied by an assay with a probe substrate as a control: UGT1A6 with 1-naphthol and UGT1A9 with propofol at a fixed substrate concentration (500 M) under identical conditions to the assays to determine the kinetic parameters for the test phenols. This value was used to normalize the V max values produced for the phenol substrate to control for any variability in the activity of the cell preparation and total amount of cell protein added.
Protein Determinations. Estimation of protein concentration was carried out using the method of Lowry et al. (1951) , on dilutions of 1:100 of the cellular sonicates with bovine serum albumin as standard.
MS-WHIM Descriptor Computation. MS-WHIM and AT-WHIM descriptors were computed using an improved in-house program based on the method of Bravi and Wikel (2000) . In this program, the WHIM mathematical strategy (Todeschini et al., 1994 ) is applied to the coordinates of the critical points of the molecular surface (Lin et al., 1994) . For each molecule, atomic three-dimensional coordinates were generated by CORINA (Gasteiger et al., 1990) , and critical points were calculated using an in-house procedure according to the method of Lin et al. (1994) . Six molecular surface propertyweighting schemes (unitary, positive and negative electrostatic potential, hydrogen-bonding acceptor, and donor capacity and hydrophobicity) are used . A total of 102 [11 directional and 6 nondirectional (Todeschini and Gramatica, 1997) for each weighting scheme] descriptors were generated per phenol substrate. These descriptors were used along with Cerius 2 (Molecular Simulations Inc., San Diego) genetic function approximation software to build a model to relate them to the log K m values. Leave-oneout cross validation was also used to generate a cross-validated r 2 (q 2 ).
Results
4-Substituted phenols were screened as potential substrates for UGT1A9 and UGT1A6 regardless of whether or not they had previously been identified as substrates. The phenols used and the structures of the 4-substitutents are shown in Fig. 1 . Twenty-four of these phenols were substrates of UGT1A9 and 12 were substrates of UGT1A6. Two of the 12 phenols glucuronidated by UGT1A6 (4-fluorophenol and 4-methoxyphenol) were turned over to such a low extent that it was not possible to accurately measure kinetic parameters using the radiochemical HPLC method. Kinetic parameters for UGT1A6 and UGT1A9 are listed in Table 1 and Table 2 (Fig. 2) . Empirically, it was noted that as the size of substituent decreased, UGT1A6 V max increased, and correspondingly the K m increased. This trend is better illustrated when the molecular volume of the substituent is plotted against V max , as the negative correlation becomes apparent (Fig. 3) . It was predicted that substrates not displaying glucuronidation activity when measured using this assay might be bound by UGT1A6 but not glucuronidated, or glucuronidated to such a low extent that no activity was measurable. Three phenols with bulky substituents, 4-n propylphenol, propyl 4-hydroxybenzoate, and 4-hydroxy biphenyl, were all shown to inhibit ethylphenol activity (K m , 551 M) significantly at a concentration of 500 M (Fig. 4) .
Application of the Cerius 2 genetic function approximation software to the experimental data produced models for UGT1A6 and UGT1A9. These models relate log K m to the AT-and MS-weighted holistic invariant molecular descriptors shown in eqs. 1 and 2. log UGT1A6 K m ϭ Ϫ233.08 ϩ JWMWGW5 Ϫ 8.75
Where JWMWGW5 is an MS-WHIM descriptor using hydrogenbond donor capacity as weight, the total symmetry descriptor. JWMWH2W2 is an MS-WHIM descriptor using positive molecular electrostatic potential as the weight, the emptiness descriptor. JWAWAW3 is the AT-WHIM descriptor using atomic mass as weight, the quadratic contribution descriptor. JWAWS3W6 is an AT-WHIM descriptor using absolute atomic partial charge as weight, the second symmetry descriptor. 
Where JWAWE3W6 is an AT-WHIM descriptor using absolute atomic partial charge as weight, the third eigen value. JWMWH2W3 is an MS-WHIM descriptor using negative molecular electrostatic potential as weight, the second emptiness descriptor. JWMWP2W4 is an MS-WHIM descriptor using hydrogen-bonding acceptor capacity as weight, the second proportion descriptor. JWAWP2W5 is an AT-WHIM descriptor using atomic polarizability as weight, the second proportion descriptor.
Discussion
Glucuronidation QSAR to date has typically relied on data garnered from literature sources for quantitative analysis. The relatively small number of reports on glucuronidation QSAR reflects the lack of appropriate data that is available for this purpose and explains why little progress has been made in this area in recent years. This is also apparent by the number of times that the same data has been analyzed either completely or in part by different groups attempting to apply this type of analysis. With the exception of one report of a partially purified rat UGT (Yin et al., 1994) , glucuronidation QSAR has been carried out with data from assays using microsomal sources of the UDP-glucuronosyltransferase enzyme (Hansch et al., 1968; Schaefer et al., 1981; Kim, 1991; Hansch and Leo, 1995) . Using rat microsomal systems for this type of work adds the complication of modeling a heterogenous population of enzymes that can display a considerable overlap in substrate specificity for the type of simple compounds that are used. Taking into account these considerations, it seems unlikely that these models derived from rat microsomes can provide much in the way of useful information. The benefit of studying isolated enzymes is that the complications introduced by trying to predict the glucuronidation activities of a heterogenous population of isoforms is avoided, and the substrate physicochemical parameters can be directly related to their influence on activity and affinity of a single active site.
The rationale behind the selection of the phenolic compounds as probe substrates is their availability, as well as permitting considerable diversity in the type and size of substituent. Furthermore, phenolic molecules were likely to be adequate substrates for the isoforms in question, providing kinetic data for the analysis, something which to date has not been attempted with expressed human UGT isoforms. The data set was intended to form the basis of a set of compounds that could be expanded to include more diverse compounds in the future and be used to evaluate the quality and value of QSAR analysis of glucuronidation.
The data presented here has been generated with single UGT isoforms with the express purpose of QSAR analysis to compare and contrast two human UGT isoforms that display a considerable overlap in substrate specificity. It is immediately clear that the same restric- The substrates are not listed in the order that they appear in Tables 1 and 2. FIG. 3. UGT1A6 V max correlated to the molecular volume of the substituent.
FIG. 4. The inhibition of UGT1A6 4-ethylphenol glucuronidation by phenols with bulky substituents.
The phenols used were 4-n propylphenol, propyl 4-hydroxybenzoate and 4-hydroxy biphenyl from left to right. The 4-ethylphenol concentration used was 500 M and the interfering phenol concentration range used was 50, 100, 250, and 500 M.
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at ASPET Journals on April 3, 2017 dmd.aspetjournals.org Downloaded from tions on substrate acceptance by UGT1A6 in comparison with UGT1A9 that have been reported previously (Ebner and Burchell, 1993) are also apparent by the results of this study. Although the potential substrates that were screened by both of the expressed isoforms only vary by way of the substituent at the 4-position, this position seems to be an important factor in whether a compound is or is not a substrate of UGT1A6. Again, UGT1A9 demonstrates proficiency toward the glucuronidation of a wide range of substituted phenols as previously reported (Ebner and Burchell, 1993) . UGT1A6 is typified by lower K m values ranging from micromolar to low millimolar values. This is the first indication of significant differences between the two isoforms as UGT1A9, in general, has lower K m values than UGT1A6. Comparing the K m values for the set of phenol substrates that are glucuronidated by both isoforms clearly indicates substantially lower K m values for UGT1A9 than UGT1A6 (Fig. 4) ; however, the ranges of V max are similar between the two.
The models generated from the kinetic data relate the K m values to four separate determinants of surface properties of the substrates. The two isoforms are related by totally different descriptors from the identical set of 112 that were originally applied to the experimental data. The correlation coefficients for the fit of the data are good and the cross-validation (q 2 ) values indicate that the predictive capability of these models is good. The application of a test set of compounds for external validation would be the ideal way to evaluate the models, but all the compounds were included in the analysis. It seems unlikely that a model generated from such simple compounds would be able to predict the K m values of more complicated structures. But this work does suggest that for a closely related set of compounds, in this case simple phenols, QSAR models can be generated quite simply, which can predict K m according to the internal validation q 2 value. The greatest problem of the data set that was used for this modeling is that it does not contain a wide range of K m values. This indicates that the structural features of the probe molecules are not diverse enough to map the sample space of the active site. Both of these isoforms are able to glucuronidate larger phenols and other bulkier molecules; hence, it seems likely that to gain more meaningful insight into substrate, UGT interactions the size and diversity of the probe substrates used need to be increased.
Another point of interest is the trend observed between UGT1A6 V max and the molecular volume. Even without the application of QSAR analysis, it was clear that UGT1A6 V max values were decreasing as the bulk of the substituent increased. Plotting the V max against molecular volume of the substrate showed an obvious trend ( Figure  3) , although plotting K m against molecular volume does not show any appreciable correlation at all. The hypothesis proposed was that if V max decreased as substrate volume increased then more bulky substrates may be accepted into the active site but may not be glucuronidated, or are glucuronidated below the limits of detection. The inhibitory effect of bulky phenols on the glucuronidation of 4-ethylphenol suggests that this might indeed be the case.
This report demonstrates the potential utility of applying QSAR analysis to glucuronidation data. The limitations of the data set are acknowledged and are presented as the starting point for building more complex models in the future, which can help predict the features of a molecule that make it acceptable as a substrate of UGT1A6 and UGT1A9. Industrial drug design is now more adept at avoiding compounds that are highly metabolized by cytochrome P450 isozymes by screening for high metabolic turnover early in development. If successful circumvention of phase I metabolism leads to the development of more potential drugs that are glucuronidated, then the next evolution in QSAR modelling for the pharmaceutical industry will require models like those suggested in this study (Ekins et al, 2000) .
